Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

FDA Approves Adjuvant Pertuzumab Regimen for HER2+ Breast Cancer

December 21st 2017

The FDA has approved pertuzumab in combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.

CDK4/6 Inhibitors Make Impact in HR-Positive Metastatic Breast Cancer

December 19th 2017

The introduction of cyclin-dependent kinase 4/6 inhibitors has resulted in a significant paradigm shift in the treatment of hormone receptor–positive breast cancer, helping to make the new agents part of rapidly developing improvements in personalized care for patients.

Dr. Domchek on the MEDIOLA Trial in Breast Cancer

December 19th 2017

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the MEDIOLA trial in breast cancer.

CHMP Issues Positive Opinion on Herzuma for HER2+ Breast, Gastric Cancers

December 19th 2017

The European Union’s CHMP has delivered a positive opinion for Herzuma (CT-P6), a trastuzumab (Herceptin) biosimilar in HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.

Precision Medicine a Necessary Component in HER2+ Breast Cancer Care

December 18th 2017

Mothaffar Fahed Rimawi, MD, discusses the significance of precision medicine in HER2-positive breast cancer, as well as the possible role of immunotherapy for this specific population.

Dr. Tripathy Discusses Lurbinectedin in Breast Cancer

December 14th 2017

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses lurbinectedin (PM01183) for patients with breast cancer.

Olaparib/Durvalumab Combo Effective for BRCA-mutant Breast Cancer

December 14th 2017

The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate of 80% for pretreated patients with germline BRCA-mutated, HER2-negative metastatic breast cancer,

Dr. King Discusses Lymph Node Resection in Breast Cancer

December 14th 2017

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses lymph node resection in breast cancer.

Dr. Tripathy Discusses Neratinib in HER2+ Breast Cancer

December 12th 2017

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.

Abemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer

December 9th 2017

The combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer.

Antibody-Drug Conjugate Active in Heavily Pretreated Metastatic TNBC

December 9th 2017

Monotherapy with an antibody drug conjugate targeting the transmembrane protein LIV-1 had encouraging antitumor activity in a phase 1 study of patients with heavily pretreated TNBC.

Gene-Based Biomarker Identifies Patients With Breast Cancer More Likely to Respond to Enzalutamide

December 9th 2017

Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.

Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers

December 9th 2017

Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.

Positive CTC Findings Linked to High Recurrence Risk in HR+ Breast Cancer

December 9th 2017

Detection of positive circulating tumor cells in the blood 5 years after a breast cancer diagnosis was associated with an increased risk for late recurrence in women with HR–positive, HER2-negative breast cancer

Pembrolizumab/Eribulin Efficacy Maintained for TNBC in Larger Dataset

December 9th 2017

Treatment with the combination of pembrolizumab (Keytruda) and eribulin (Halaven) demonstrated a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.

Dr. Burstein Discusses Key Updates from the SOFT Trial

December 9th 2017

Harold Burstein, MD, PhD, medical oncologist, Dana-Farber Cancer Institute discusses some key findings from the follow-up data from the SOFT trial.

Even Moderate Weight Loss Helps Prevent Breast Cancer in Postmenopausal Women

December 9th 2017

Losing even some extra weight significantly reduces the risk of breast cancer for postmenopausal women, expert says.

Neoadjuvant Abemaciclib Active in Early Breast Cancer

December 8th 2017

Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.

CDK4/6 Improved PFS in Older Women with HR+ Metastatic Breast Cancer

December 8th 2017

Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival benefit similar to that seen in their younger counterparts

Talazoparib Improves PFS in BRCA-Positive Breast Cancer

December 8th 2017

The PARP inhibitor talazoparib reduced the risk of disease progression or death by 46% versus chemotherapy in patients with BRCA-positive advanced breast cancer.